Fitness variations and their impact on the evolution of antiretroviral drug resistance.
about
Current perspectives on HIV-1 antiretroviral drug resistanceViral quasispecies evolutionA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityMutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants.Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics.The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Genetic Consequences of Antiviral Therapy on HIV-1.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralizationProtease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation ProcessInduction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.
P2860
Q26852626-41DF59C4-D18B-420E-83AE-DDCCB89CC3C0Q27013917-F814AE1D-1AEF-42D7-9587-5E387168D800Q28533996-5CF6557C-63DA-4BA1-855F-543757F138C4Q33330469-EAD20BAE-9117-4A4D-9A25-67708906147EQ33687232-376A8A64-88DD-45EE-8CEB-C26792C38A33Q35042225-AB27A6BC-DD5C-413B-871A-F5B21DAAAA05Q35773113-49857C57-AAF5-4E00-92CE-0A037D4F3168Q35842525-D8F80920-40E9-464D-ABEE-027CFE60F5E6Q37192174-238B74BB-955F-45D7-AC9C-5670DF3E6DF1Q37227218-35427F89-DB91-4E35-BC99-866C00AC96BBQ38543385-85F73BDF-61F2-48CB-A0F6-D6876FCF56DEQ38966123-4FADA90E-0052-4E95-8046-07C01F384E00Q39389791-81E9779A-2174-493C-93E6-18C6E23E548DQ41844750-01EC8B5E-C8BD-4DD6-8DE3-9359D27E86AFQ41950632-75E6E2E2-5D4F-42DA-8315-2AB0F0126057Q43257021-897921F6-EE98-4349-A21B-EE389F5A8337
P2860
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@ast
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@en
type
label
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@ast
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@en
prefLabel
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@ast
Fitness variations and their impact on the evolution of antiretroviral drug resistance.
@en
P50
P356
P1476
Fitness variations and their impact on the evolution of antiretroviral drug resistance
@en
P2093
Miguel E Quiñones-Mateu
P304
P356
10.2174/1568005033481033
P577
2003-12-01T00:00:00Z